Cited 0 times in Scipus Cited Count

Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report

DC Field Value Language
dc.contributor.authorKim, HJ-
dc.contributor.authorNoh, WC-
dc.contributor.authorNam, SJ-
dc.contributor.authorPark, BW-
dc.contributor.authorLee, ES-
dc.contributor.authorIm, SA-
dc.contributor.authorJung, YS-
dc.contributor.authorYoon, JH-
dc.contributor.authorKang, SS-
dc.contributor.authorPark, KH-
dc.contributor.authorLee, SJ-
dc.contributor.authorJeong, J-
dc.contributor.authorLee, MH-
dc.contributor.authorCho, SH-
dc.contributor.authorKim, SY-
dc.contributor.authorKim, HA-
dc.contributor.authorHan, SH-
dc.contributor.authorHan, W-
dc.contributor.authorHur, MH-
dc.contributor.authorKim, S-
dc.contributor.authorAhn, SH-
dc.date.accessioned2023-01-05T03:03:49Z-
dc.date.available2023-01-05T03:03:49Z-
dc.date.issued2021-
dc.identifier.issn0959-8049-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23784-
dc.description.abstractBackground: Adding ovarian function suppression (OFS) after chemotherapy improves survival in young women with moderate- and high-risk breast cancer. Assessment of ovarian function restoration after chemotherapy becomes critical for subsequent endocrine treatment and addressing fertility issues. Patients and methods: In the adding OFS after chemotherapy trial, patients who resumed ovarian function up to 2 years after chemotherapy were randomised to receive either 5 years of tamoxifen or adding 2 years of OFS with tamoxifen. Ovarian function was evaluated from enrolment to randomisation, and patients who did not randomise because of amenorrhoea for 2 years received tamoxifen and were followed up for 5 years. Prospectively collected consecutive hormone levels (proportion of patients with premenopausal follicle-stimulating hormone [FSH] levels <30 mIU/mL and oestradiol [E2] levels ≥40 pg/mL) and history of menstruation were available for 1067 patients with breast cancer. Results: Over 5 years of tamoxifen treatment, 69% of patients resumed menstruation and 98% and 74% of patients satisfied predefined ovarian function restoration as per serum FSH and E2 levels, respectively. Menstruation was restored in 91% of patients younger than 35 years at baseline, but in only 33% of 45-year-old patients over 5 years. Among these patients, 41% experienced menstruation restoration within 2 years after chemotherapy and 28% slowly restored menstruation after 2–5 years. Younger age (<35 years) at baseline, anthracycline without taxanes and ≤90 days of chemotherapy were predictors of menstruation restoration. Conclusions: During 5 years of tamoxifen treatment after chemotherapy, two-thirds of the patients experienced menstruation restoration, especially patients younger than 35 years. Young age, Adriamycin without taxanes and short duration of chemotherapy appeared to have a positive effect on ovarian reserves in the long term. Trial registration: ClinicalTrials.gov identifier: NCT00912548.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAge Factors-
dc.subject.MESHAntineoplastic Agents, Hormonal-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBiomarkers-
dc.subject.MESHBreast Neoplasms-
dc.subject.MESHEstradiol-
dc.subject.MESHFemale-
dc.subject.MESHFollicle Stimulating Hormone, Human-
dc.subject.MESHHumans-
dc.subject.MESHMenstruation-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOvary-
dc.subject.MESHPremenopause-
dc.subject.MESHRecovery of Function-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHTamoxifen-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleFive-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report-
dc.typeArticle-
dc.identifier.pmid34010788-
dc.subject.keywordChemotherapy-
dc.subject.keywordE2-
dc.subject.keywordFSH-
dc.subject.keywordMenstruation-
dc.subject.keywordOvarian function-
dc.subject.keywordTamoxifen-
dc.contributor.affiliatedAuthorJung, YS-
dc.contributor.affiliatedAuthorHan, SH-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.ejca.2021.03.017-
dc.citation.titleEuropean journal of cancer (Oxford, England : 1990)-
dc.citation.volume151-
dc.citation.date2021-
dc.citation.startPage190-
dc.citation.endPage200-
dc.identifier.bibliographicCitationEuropean journal of cancer (Oxford, England : 1990), 151. : 190-200, 2021-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1879-0852-
dc.relation.journalidJ009598049-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse